EZR and soft tissue sarcoma: Although the underlying mechanisms involved in the effects of ezrin on the progression of bone and soft tissue sarcomas remain unclear and need further investigation, the results of our analysis showed that ezrin overexpression was significantly correlated with more advanced progression in patients with bone and soft tissue sarcomas, which might contribute to the strengths of the survival meta‐analysis.